Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases
Status:
Recruiting
Trial end date:
2028-01-09
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the best dose of total body irradiation with astatine-211
BC8-B10 monoclonal antibody for the treatment of patients with nonmalignant diseases
undergoing hematopoietic cell transplant. Radiation therapy uses high energy gamma rays to
kill cancer cells and shrink tumors. Astatine-211-labeled BC8-B10 monoclonal antibody is a
monoclonal antibody, called anti-CD45 monoclonal antibody BC8-B10, linked to a
radioactive/toxic agent called astatine 211. Anti-CD45 monoclonal antibody BC8-B10 is
attached to CD45 antigen positive cancer cells in a targeted way and delivers astatine 211 to
kill them. Giving astatine-211 BC8-B10 monoclonal antibody and total-body irradiation before
a donor stem cell transplant may help stop the growth of cells in the bone marrow, including
normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's
immune system from rejecting the donor's stem cells.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center
Collaborators:
National Cancer Institute (NCI) National Heart, Lung, and Blood Institute (NHLBI)